Stockscreener 앱 받기
0.1799
21.52%
-0.0301
전일 마감가:
$0.21
열려 있는:
$0.15
하루 거래량:
106.71K
Relative Volume:
67.08
시가총액:
$N/A
수익:
-
순이익/손실:
$-16.08M
주가수익비율:
-0.00523
EPS:
-34.43
순현금흐름:
$-11.54M
1주 성능:
-21.52%
1개월 성능:
-80.61%
6개월 성능:
-86.27%
1년 성능:
-97.18%
1일 변동 폭
$0.15
$0.1919
1주일 범위
$0.15
$0.1919
52주 변동 폭
$0.15
$0.1919
Bio Path Holdings Inc Stock (BPTH) Company Profile
BPTH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.1799 | 0 | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.50 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-03-11 | 개시 | ROTH Capital | Buy |
| 2017-11-13 | 재확인 | H.C. Wainwright | Buy |
| 2016-08-10 | 재확인 | Maxim Group | Buy |
| 2016-04-18 | 개시 | Rodman & Renshaw | Buy |
| 2014-06-02 | 재개 | Maxim Group | Buy |
| 2014-05-09 | 개시 | Maxim Group | Buy |
모두보기
Bio Path Holdings Inc 주식(BPTH)의 최신 뉴스
Global Chronic Myeloid Leukemia (CML) Treatment Market To Expand At A CAGR Of 7% Reaching $$11.39 Billion B... - WhaTech
Bio-Path (BPTH): Promising Preclinical Results for Obesity Treat - GuruFocus
Bio-Path Holdings Achieves Third Pre-Clinical Milestone Confirming Potential of BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - The Manila Times
Microbix Presenting at the 2025 Bloom Burton Conference - The Manila Times
Acute Myeloid Leukemia Drugs Market 2034: EMA, PDMA, FDA - openPR.com
StockNews.com Begins Coverage on Bio-Path (NASDAQ:BPTH) - Defense World
Bio-Path Holdings, Inc. to Host Earnings Call - ACCESS Newswire
Cutaneous T-Cell Lymphoma Clinical Trials and Studies 2025: - openPR.com
Cutaneous T-Cell Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Longleaf Partners Fund Believes PayPal Holdings (PYPL) Has a Compelling Path Forward - Yahoo Finance
Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com - Defense World
StockNews.com Initiates Coverage on Bio-Path (NASDAQ:BPTH) - Defense World
TIBSOVO's Continued Success Solidifies Its Position as a Leader in IDH1 Mutant Space | DelveInsight - The Malaysian Reserve
Indo-Asian News Service - Indo-Asian News Service (IANS)
Acute Myeloid Leukemia Treatment Market 2034: Clinical Trials, - openPR.com
Small Interfering RNA (siRNA) Therapeutics Market Revenue Report with Forecast to 2031 - openPR.com
Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com - Defense World
What is Roth Capital’s Forecast for Bio-Path Q1 Earnings? - Defense World
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q2 2024 Earnings Call Transcript - MSN
Bio-Path Holdings Reports 2024 Financial Results and Progress - TipRanks
Bio-Path Holdings Reports Full Year 2024 Financial Results - MarketScreener
Bio-Path Slashes Annual Losses While Breakthrough Obesity Treatment Shows Promise - Stock Titan
Cutaneous T-Cell Lymphoma (CTCL) Treatment Market 2034: Clinical Trials, Medication, Prevalence, Statistics, Revenue, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - Barchart
North American Morning Briefing : Tariff Jitters -2- - Marketscreener.com
Small Interfering RNA (siRNA) Therapeutics Market Forecast to Expand with Growing Investment in RNA Therape... - WhaTech
Thyroid Cancer Drugs Market Set For 13% Growth, Reaching $2.2 Billion By 2029 - WhaTech
Antisense Oligonucleotide Therapeutics Market Current Scenario Analysis Report - InsightAce Analytic
North American Morning Briefing : Stock Futures Fall as Focus Shifts From Fed to Tariffs - Marketscreener.com
Bio-Path Holdings Reports Promising Pre-Clinical Results - TipRanks
Bio-Path reports results from preclinical studies of BP1001-A - TipRanks
Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients - Marketscreener.com
Bio-Path (NASDAQ:BPTH) Coverage Initiated at StockNews.com - Defense World
Breakthrough: Bio-Path's Novel Drug Could Transform Diabetes and Obesity Treatment - Stock Titan
Future-Proofing Growth Non-Viral Drug Delivery Systems - openPR
Bio-Path (NASDAQ:BPTH) Now Covered by StockNews.com - Defense World
Tevogen Bio Holdings Inc. (TVGN) Secures $8M Grant, Accelerates AI Initiatives with Microsoft - Yahoo Finance
North American Morning Briefing : Stock Futures -2- -March 07, 2025 at 06:29 am EST - Marketscreener.com
BIO-PATH HOLDINGS Earnings Preview: Recent $BPTH Insider Trading, Hedge Fund Activity, and More - Nasdaq
Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.com - Defense World
Bio-Path (BPTH) Expected to Announce Earnings on Thursday - Defense World
Global Peptide Synthesis Market to Surge at a Tremendous CAGR of ~10% by 2032 | DelveInsight - GlobeNewswire
Stocks to Buy: Many Have Chosen These Today April 5th - ACCESS Newswire
Biotech Alert: Searches spiking for these stocks today - TipRanks
C-COM Antenna Receives Eutelsat Type Approval - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Alarm.com (ALRM) Q4 Earnings: What To Expect - The Globe and Mail
Why Tight Corporate-U.S. Treasury Yield Spreads Signal Good News for Ag Markets Prices - The Globe and Mail
United States shares higher at close of trade; Dow Jones Industrial Average up 0.02% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.02% - Investing.com
Bio Path Holdings Inc (BPTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):